T1	Participants 478 571	small-cell lung cancer (SCLC) patients who responded to six courses of induction chemotherapy
T2	Participants 664 814	235 eligible patients initially registered, 91 were randomized to receive maintenance therapy, including seven patients who were no longer responding.